Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

Please provide your email address to receive an email when new articles are posted on . Focal cortex stimulation with an implantable device reduced seizure activity in more than 50% of participants at ...

Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...

Marinus Pharmaceuticals announced top-line results from the Phase 3 clinical trial of ganaxolone in adults with drug-resistant focal onset seizures. Marinus Pharmaceuticals announced top-line results ...

About 60-70% of focal epilepsy patients achieve seizure control with first-line antiseizure medications (ASMs). Lamotrigine and levetiracetam demonstrate high efficacy and tolerability for seizure ...

Lacosamide Vimpat (lacosamide) can help manage focal seizures in adults and children 4 years and older. It can be used alone (monotherapy) or with another AED (adjunctive therapy). Lacosamide reduces ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy ...

(Reuters) - Marinus Pharmaceuticals Inc said it plans to stop development of its treatment for drug-resistant focal onset seizures in adults after it failed a late-stage trial, sending the company's ...

Patients with focal nonmotor seizures experience a "disproportionate delay to diagnosis" compared with those with focal motor seizures, especially among teens, new research suggests. Retrospective ...

Emerging clinical and autopsy evidence points to late-onset epilepsy as a potentially distinct, neurodegeneration-related form of epilepsy, with many cases still unexplained.